The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.
Dea Belazi
Advertisement
Dea Belazi is President and CEO of AscellaHealth.
Articles by Dea Belazi
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Amgen’s Tarlatamab Approved in China
2
Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement
3
Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer
4
Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats
5